Development of adenovirus vectors encoding rat complement regulators for use in therapy in rodent models of inflammatory diseases

Journal of Immunology

Volumn 163, Issue 12, 1999, Pages 6834-6840

  McGrath, Yvonne ^a   Wilkinson, Gavin W G ^a   Spiller, O Brad ^a   Morgan, B Paul ^a  

^a CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENT INHIBITOR; VIRUS VECTOR;

ADENOVIRUS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; COMPLEMENT INHIBITION; CONTROLLED STUDY; FLOW CYTOMETRY; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IMMUNOFLUORESCENCE TEST; IMMUNOPHARMACOLOGY; INFLAMMATORY DISEASE; NONHUMAN; PRIORITY JOURNAL; RAT; TRANSGENE;

ADENOVIRIDAE; ANIMALS; ANTIGENS, CD55; ANTIGENS, CD59; ANTIGENS, SURFACE; BETA-GALACTOSIDASE; CELL LINE, TRANSFORMED; COMPLEMENT C3; COMPLEMENT INACTIVATOR PROTEINS; CYTOTOXICITY, IMMUNOLOGIC; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; FIBROBLASTS; GENETIC VECTORS; GLYCOSYLPHOSPHATIDYLINOSITOLS; HUMANS; INFLAMMATION; INJECTIONS, INTRA-ARTERIAL; PHOSPHATIDYLINOSITOL DIACYLGLYCEROL-LYASE; PHOSPHOLIPASE C; RATS; RECEPTORS, CELL SURFACE; RECEPTORS, COMPLEMENT; STAINING AND LABELING; SYNOVIAL MEMBRANE;

EID: 0032760929     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (51)

1. Schifferli, J. A., Y. C. Ng, and D. K. Peters. 1986. The role of complement and its receptor in the elimination of immune complexes. N. Engl. J. Med. 315:488.
2. Morgan, B. P., and M. J. Walport. 1991. Complement deficiency and disease. Immunol. Today 12:301.
3. Morgan, B. P. 1994. Clinical complementology: recent progress and future trends. Eur. J. Clin. Invest. 24:219.
4. Morgan, B. P. 1992. Effects of the membrane attack complex of complement on nucleated cells. Curr. Top. Microbiol. Immunol. 178:115.
5. Morgan, B. P., and C. L. Harris. 1999. Complement Regulatory Proteins. Academic Press, London.
6. Weisman, H. F., T. Bartow, M. K. Leppo, H. C. Marsh, Jr., G. R. Carson, M. F. Concino, M. P. Boyle, K. H. Roux, M. L. Weisfeldt, and D. T. Fearon. 1990. Soluble human complement receptor type 1: in vivo inhibitor of complement suppressing post-ischemic myocardial inflammation and necrosis. Science 249:146.
7. Hill, J., T. F. Lindsay, F. Ortiz, C. G. Yeh, H. B. Hechtman, and F. D. Moore, Jr. 1992. Soluble complement receptor type 1 ameliorates the local and remote organ injury after intestinal ischemia-reperfusion in the rat. J. Immunol. 149:1723.
8. Pemberton, M., G. Anderson, V. Vetvicka, D. E. Justus, and G. D. Ross. 1993. Microvascular effects of complement blockade with soluble recombinant CRI on ischemia/reperfusion injury of skeletal muscle. J. Immunol. 150:5104.
9. Piddlesden, S. J., M. K. Storch, M. Hibbs, A. M. Freeman, H. Lassmann, and B. P. Morgan. 1994. Soluble recombinant complement receptor 1 inhibits inflammation and demyelination in antibody-mediated demyelinating experimental allergic encephalomyelitis. J. Immunol. 152:5477.
10. Chavez-Cartaya, R. E., G. P. DeSola, L. Wright, N. V. Jamieson, and D. J. White. 1995. Regulation of the complement cascade by soluble complement receptor type 1: protective effect in experimental liver ischemia and reperfusion. Transplantation 59:1047.
11. Jung, S., K. V. Toyka, and H. P. Hartung. 1995. Soluble complement receptor type 1 inhibits experimental autoimmune neuritis in Lewis rats. Neurosci. Lett. 200:167.
12. Piddlesden, S. J., S. Jiang, J. L. Levin, A. Vincent, and B. P. Morgan. 1996. Soluble complement receptor 1 (sCRI) protects against experimental autoimmune myasthenia gravis. J. Neuroimmunol. 71:173.
13. Goodfellow, R. M., A. S. Williams, J. L. Levin, B. D. Williams, and B. P. Morgan. 1997. Local therapy with soluble complement receptor 1 (sCRI) suppresses inflammation in rat mono-articular arthritis. Clin. Exp. Immunol. 110:45.
14. Hughes, T. R., S. J. Piddlesden, J. D. Williams, R. A. Harrison, and B. P. Morgan. 1992. Isolation and characterization of a membrane protein from rat erythrocytes which inhibits lysis by the membrane attack complex of rat complement. Biochem. J. 284:169.
15. Hinchliffe, S. J., O. B. Spiller, N. K. Rushmere, and B. P. Morgan. 1998. Molecular cloning and functional characterization of the rat analogue of human decay-accelerating factor (CD55). J. Immunol. 161:5695.
16. Mead, R. M., S. J. Hinchliffe, and B. P. Morgan. 1999. Molecular cloning, expression and characterisation of the rat analogue of human membrane cofactor protein (MCP/CD46). Immunology. 98:137.
17. Rushmere, N. K., S. Tomlinson, and B. P. Morgan. 1997. Expression of rat CD59: functional analysis confirms lack of species selectivity and reveals that glycosylation is not required for function. Immunology 90:640.
18. Morgan, B. P., and S. Meri. 1994. Membrane proteins that protect against complement lysis. Springer Semin. Immunopathol. 15:369.
19. Quigg, R. J., M. L. Galishoff, A. E. d. Sneed, and D. Kim. 1993. Isolation and characterization of complement receptor type 1 from rat glomerular epithelial cells. Kidney Int. 43:730.
20. Takizawa, H., N. Okada, and H. Okada. 1994. Complement inhibitor of rat cell membrane resembling mouse Crry/p65. J. Immunol. 152:3032.
21. Funabashi, K., N. Okada, S. Matsuo, T. Yamamoto, B. P. Morgan, and H. Okada. 1994. Tissue distribution of complement regulatory membrane proteins in rats. Immunology 81:444.
22. Quigg, R. J., C. F. Lo, J. J. Alexander, A. E. Sneed, 3rd. and G. Moxley. 1995. Molecular characterization of rat Crry: widespread distribution of two alternative forms of Crry mRNA. Immunogenetics 42:362.
23. Quigg, R. J., C. He, A. Lim, D. Berthiaume, J. J. Alexander, D. Kraus, and V. M. Holers. 1998. Transgenic mice overexpressing the complement inhibitor crry as a soluble protein are protected from antibody-induced glomerular injury. J. Exp. Med. 188:1321.
24. Quigg, R. J., Y. Kozono, D. Berthiaume, A. Lim, D. J. Salant, A. Weinfeld, P. Griffin, E. Kremmer, and V. M. Holers. 1998. Blockade of antibody-induced glomerulonephritis with Crry-Ig, a soluble murine complement inhibitor. J. Immunol. 160:4553.
25. Spiller, O. B., C. L. Harris, and B. P. Morgan. 1999. Efficient generation of monoclonal antibodies against surface-expressed proteins by hyperexpression in rodent cells. J. Immunol. Methods 224:51.
26. van den Berg, C. W., O. M. Williams, and B. P. Morgan. 1994. Presence of a dysfunctional form of CD59 on a CD59+ subclone of the U937 cell line. Immunology 81:637.
27. Wilkinson, G. W., and A. Akrigg. 1992. Constitutive and enhanced expression from the CMV major IE promoter in a defective adenovirus vector. Nucleic Acids Res. 20:2233.
28. Graham, F. L., J. Smiley, W. C. Russell, and R. Nairn. 1977. Characteristics of a human cell line transformed by DNA from human adenovirus type 5. J. Gen. Virol. 36:59.
29. McGrory, W. J., D. S. Bautista, and F. L. Graham. 1988. A simple technique for the rescue of early region 1 mutations into infectious human adenovirus type 5. Virology 163:614.
30. Graham, F. L., and A. J. v. d. Eb. 1973. A new technique for the assay of infectivity of human adenovirus 5 DNA. Virology 52:456.
31. Graham, F. L., and L. Prevec. 1995. Methods for construction of adenovirus vectors. In Molecular Biotechnology, Vol. 3. Humana Press, Clifton, NJ, p. 207.
32. Burleson, F. G., T. M. Chambers, and D. L. Wiedbrauk. 1992. Introduction to quantal virus assays. In Virology: A Laboratory Manual. Academic Press, London, p. 53.
33. Smith, T. A., M. G. Mehaffey, D. B. Kayda, J. M. Saunders, S. Yei, B. C. Trapnell, A. McClelland, and M. Kaleko. 1993. Adenovirus mediated expression of therapeutic plasma levels of human factor IX in mice. Nat. Genet. 5:397.
34. Kozarsky, K. F., D. R. McKinley, L. L. Austin, S. E. Raper, L. D. Stratford-Perricaudet, and J. M. Wilson. 1994. In vivo correction of low density lipoprotein receptor deficiency in the Watanabe heritable hyperlipidemic rabbit with recombinant adenoviruses. J Biol. Chem. 269:13695.
35. Kay, M. A., A. X. Holterman, L. Meuse, A. Gown, H. D. Ochs, P. S. Linsley, and C. B. Wilson. 1995. Long-term hepatic adenovirus-mediated gene expression in mice following CTLA4Ig administration. Nat. Genet. 11:191.
36. Kozarsky, K. F., and J. M. Wilson. 1993. Gene therapy: adenovirus vectors. Curr. Opin. Genet. Dev. 3:499.
37. Roessler, B. J., E. D. Allen, J. M. Wilson, J. W. Hartman, and B. L. Davidson. 1993. Adenoviral-mediated gene transfer to rabbit synovium in vivo. J. Clin. Invest. 92:1085.
38. Charreau, B., L. Tesson, A. David, A. Cassard, B. Quantin, A. Pavirani, J.-P. Soulillou, and I. Anegon. 1997. Adenovirus-mediated expression of human CD59 on xenogenic endothelial cells: protection against human complement-mediated lysis and induction of cellular activation by adenoviral transduction. Xenotransplantation 4:212.
39. Matsuo, S., S. Ichida, H. Takizawa, N. Okada, L. Baranyi, A. Iguchi, B. P. Morgan, and H. Okada. 1994. In vivo effects of monoclonal antibodies that functionally inhibit complement regulatory proteins in rats. J. Exp. Med. 180: 1619.
40. Hatanaka, Y., Y. Yuzawa, K. Nishikawa, A. Fukatsu, N. Okada, H. Okada, M. Mizuno, and S. Matsuo. 1995. Role of a rat membrane inhibitor of complement in anti-basement membrane antibody-induced renal injury. Kidney Int. 48: 1728.
41. Quigg, R. J., V. M. Holers, B. P. Morgan, and A. E. Sneed, 3rd. 1995. Crry and CD59 regulate complement in rat glomerular epithelial cells and are inhibited by the nephritogenic antibody of passive Heymann nephritis. J. Immunol. 154:3437.
42. Kojima, A., K. Iwata, T. Seya, M. Matsumoto, H. Ariga, J. P. Atkinson, and S. Nagasawa. 1993. Membrane cofactor protein (CD46) protects cells predominantly from alternative complement pathway-mediated C3-fragment deposition and cytolysis. J. Immunol. 151:1519.
43. Devaux, P., D. Christiansen, M. Fontaine, and D. Gerlier. 1999. Control of C3b and C5b deposition by CD46 (membrane cofactor protein) after alternative but not classical complement activation. Eur. J. Immunol. 29:815.
44. Cochrane, C. G. 1984. The role of complement in experimental disease models. Springer Semin. Immunopathol. 7:263.
45. Brodeur, J. P., S. Ruddy, L. B. Schwartz, and G. Moxley. 1991. Synovial fluid levels of complement SC5b-9 and fragment Bb are elevated in patients with rheumatoid arthritis. Arthritis Rheum. 34:1531.
46. Oleesky, D. A., R. H. Daniels, B. D. Williams, N. Amos, and B. P. Morgan. 1991. Terminal complement complexes and C1/C1 inhibitor complexes in rheumatoid arthritis and other arthritic conditions. Clin. Exp. Immunol. 84:250.
47. Kemp, P. A., J. H. Spragg, J. C. Brown, B. P. Morgan, C. A. Gunn, and P. W. Taylor. 1992. Immunohistochemical determination of complement activation in joint tissues of patients with rheumatoid arthritis and osteoarthritis using neoantigen-specific monoclonal antibodies. J. Clin. Lab. Immunol. 37:147.
48. Jones, J., I. Laffafian, A. M. Cooper, B. D. Williams, and B. P. Morgan. 1994. Expression of complement regulatory molecules and other surface markers on neutrophils from synovial fluid and blood of patients with rheumatoid arthritis. Br. J. Rheumatol. 33:707.
49. Fava, R. A., C. Gates, and A. S. Townes. 1993. Critical role of peripheral blood phagocytes and the involvement of complement in tumour necrosis factor enhancement of passive collagen-arthritis. Clin. Exp. Immunol. 94:261.
50. Wang, Y., S. A. Rollins, J. A. Madri, and L. A. Matis. 1995. Anti-C5 monoclonal antibody therapy prevents collagen-induced arthritis and ameliorates established disease. Proc. Natl. Acad. Sci. USA 92:8955.
51. Le, C. H., A. G. Nicolson, A. Morales, and K. L. Sewell. 1997. Suppression of collagen-induced arthritis through adenovirus-mediated transfer of a modified tumor necrosis factor alpha receptor gene. Arthritis Rheum. 40:1662.